Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Multimodal profiling establishes ovarian fibrosis as a measurable and targetable hallmark of human reproductive aging

Created on 09 Sep 2026

Authors

Hughes, L., Zaniker-Gomez, E., Devrukhar, P., Biswas, S., Trofimchuk, A., Atazhanova, T., Riley, J., Kleinhans, A., Zhang, M., Holm Nielsen, S., Karsdal, M., Stout, M., Babayev, E., Duncan, F.

Abstract

ABSTRACT Ovarian aging underpins infertility, systemic morbidity, and mortality in women. Stromal fibrosis is implicated in ovarian aging but has not been defined in the human ovary in situ. We integrated shear wave elastography (SWE), extracellular matrix (ECM) neoepitope fingerprinting, and singlecell RNA sequencing of follicular fluid aspirates within the same individual to comprehensively profile ovarian fibrosis. In an age-stratified cohort (<33 and >37 years; N=32), age predicted ovarian stiffness, while mean stiffness was independently associated with reduced oocyte yield and follicular efficiency. ECM profiling revealed a dynamic fibrotic index favoring formation over degradation products. Single-cell transcriptomics demonstrated an age-associated fibroinflammatory stromal program enriched in pro-fibrotic pathways with stromal-immune crosstalk. In a larger validation cohort (25-45 years; N=100), age was similarly associated with ovarian stiffness. Thus, ovarian fibrosis is a quantifiable hallmark of human reproductive aging and represents a robust potential non-invasive biomarker and target for therapeutic intervention.

Preprint server: bioRxiv
The authors list and abstract were imported from bioRxiv on 09 Sep 2026.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this preprint? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 21
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement